Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, Anita Rimanti et al.|The Lancet Oncology|2022Cited by 50
Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone et al.|International Journal of Cancer|2019Cited by 20
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|ESMO Open|2021Cited by 12
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trialFrancesca Poggio, Lucia Del Mastro, Eva Blondeaux et al.|ESMO Open|2024Cited by 5
Eribulin in combination with bevacizumab as second-line treatment for HER2–negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|Research Square|2020Cited by 1